PST-674
Dementia in Down Syndrome (Alzheimer's pathology)
Key Facts
About Pharmasum Therapeutics
Pharmasum Therapeutics is a preclinical-stage biotech targeting dementia, one of the largest unmet medical needs, through inhibition of the DYRK1A kinase. Its lead candidate, PST-674, is a small molecule developed using advanced drug design and X-ray crystallography, with a strategic clinical entry point in Down syndrome-associated dementia due to a strong genetic rationale. The company, operating from Norway and the UK, plans to conduct a PoC study before partnering for Phase 3 development, aiming to capture value in a projected $40 billion global dementia therapy market by 2030.
View full company profileAbout Pharmasum Therapeutics
Pharmasum Therapeutics is a preclinical-stage biotech targeting dementia, one of the largest unmet medical needs, through inhibition of the DYRK1A kinase. Its lead candidate, PST-674, is a small molecule developed using advanced drug design and X-ray crystallography, with a strategic clinical entry point in Down syndrome-associated dementia due to a strong genetic rationale. The company, operating from Norway and the UK, plans to conduct a PoC study before partnering for Phase 3 development, aiming to capture value in a projected $40 billion global dementia therapy market by 2030.
View full company profileAbout Pharmasum Therapeutics
Pharmasum Therapeutics is a preclinical-stage biotech targeting dementia, one of the largest unmet medical needs, through inhibition of the DYRK1A kinase. Its lead candidate, PST-674, is a small molecule developed using advanced drug design and X-ray crystallography, with a strategic clinical entry point in Down syndrome-associated dementia due to a strong genetic rationale. The company, operating from Norway and the UK, plans to conduct a PoC study before partnering for Phase 3 development, aiming to capture value in a projected $40 billion global dementia therapy market by 2030.
View full company profile